PDCD1 and colon adenocarcinoma: Simultaneous blockade of PD-1 and LAG-3 synergizes to enhance anti-tumor CTLs activity and reduces tumor growth in a colon adenocarcinoma model [36], a chronic lymphocytic leukemia (CLL) model [37], and a malignant pleural mesothelioma model [38].